San Diego Digestive Diseases Research Center

圣地亚哥消化疾病研究中心

• 批准号: 10617213
• 负责人: LARS ECKMANN
• 金额: $ 118.46万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10617213
• 关键词: Acceleration; Animal Model; Area; Basic Science; Biomedical Research; California; Cell Culture Techniques; Clinical; Clinical Investigator; Clinical Research; Collaborations; Communication; Complement; Development; Digestive System Disorders; Direct Costs; Disease; Effectiveness; Environment; Faculty; Fostering; Funding; Gastrointestinal Diseases; Gastrointestinal tract structure; Goals; Health; Human; Immune response; Immunity; Individual; Infection; Inflammation; Inflammatory; Inflammatory Bowel Diseases; Inflammatory Response; Infrastructure; Institution; Investments; Laboratory Research; Link; Liver; Liver diseases; Mentors; Mission; National Institute of Diabetes and Digestive and Kidney Diseases; Patient Care; Phenotype; Pre-Clinical Model; Prevention; Productivity; R24; Research; Research Personnel; Research Support; Resources; Role; Scientist; Series; Services; Specimen; System; Technology; Translational Research; Universities; Work; base; career; cost effective; design; flexibility; functional genomics; gastrointestinal; high risk; host-microbe interactions; human tissue; improved; innovation; lectures; medical schools; member; microbiome research; mouse model; next generation; novel; patient population; preclinical study; programs; repository; research and development; symposium; web site

Summary The San Diego Digestive Diseases Research Center is founded on a research base of 33 outstanding investigators with current digestive diseases-relevant funding of $15,689,402 in total annual direct costs, of which $5,711,412 (36.4%) are from NIDDK. The overall mission of the Center is to support basic, translational and clinical research that will lead to improved treatment and prevention of inflammatory diseases of the digestive system. The primary goal of the Center is to provide services to the research laboratories of a consortium of four adjacent research institutions in the San Diego area that will foster research productivity and new research directions, and encourage productive collaborations. Another major goal of the San Diego Digestive Diseases Research Center is to enhance new digestive diseases research through Pilot/Feasibility and Enrichment programs. The Center supports three interrelated Biomedical Research Cores that are designed to enhance the research potential and productivity of the Center members. The Human Translational Core builds upon existing expertise in clinical and translational research to provide access to human specimens and leverages unique existing repositories of inflammatory bowel disease and liver diseases. The Preclinical Models Core facilitates and assists in characterizing and understanding of gastrointestinal and liver diseases using murine models. The Microbiomics and Functional Genomics Core provides cutting-edge and cost-effective access to sequencing-based technologies in microbiomics and functional genomics. Furthermore, an Administrative Core supports the Center administratively and coordinates the Pilot/Feasibility and Enrichment programs. Together, these Cores provide high-quality and state-of-the-art research resources to increase collaborative activity and effectiveness of the members, and promote the development of junior investigators. Combined with the Pilot/Feasibility and Enrichment programs, the San Diego Digestive Diseases Research Center will complement a strong cadre of scientists focused on a range of important inflammatory diseases of the gastrointestinal tract and liver. By creating a unique environment to nurture novel research ideas and interactions, the San Diego Digestive Diseases Research Center presents a unique opportunity to integrate clinical and bench research to advance the basic understanding of digestive diseases, and enhance the health and care of patients suffering from those diseases.

概括 圣地亚哥消化疾病研究中心由 33 名杰出的研究人员组成 目前消化系统疾病相关经费为 15,689,402 美元的研究人员，每年直接费用总额为 其中 5,711,412 美元（36.4%）来自 NIDDK。该中心的总体使命是支持基础、转化 和临床研究将改善炎症性疾病的治疗和预防 消化系统。该中心的主要目标是为研究实验室提供服务 由圣地亚哥地区四个相邻研究机构组成的联盟，将提高研究生产力和 新的研究方向，并鼓励富有成效的合作。圣地亚哥的另一个主要目标 消化疾病研究中心将通过试点/可行性研究加强新的消化疾病研究 和浓缩计划。该中心支持三个相互关联的生物医学研究核心： 旨在提高中心成员的研究潜力和生产力。人类翻译 核心建立在临床和转化研究方面的现有专业知识的基础上，为人类提供机会 标本并利用独特的现有炎症性肠病和肝脏疾病存储库。这 临床前模型核心促进并协助表征和理解胃肠道和肝脏 使用小鼠模型研究疾病。微生物组学和功能基因组学核心提供了尖端和 以具有成本效益的方式获得微生物组学和功能基因组学中基于测序的技术。 此外，行政核心为中心提供行政支持并协调试点/可行性研究 和浓缩计划。这些核心共同提供高质量和最先进的研究资源 提高会员的协作活力和效率，促进青少年的发展 调查人员。结合试点/可行性和丰富计划，圣地亚哥消化系统疾病 研究中心将补充一支强大的科学家队伍，专注于一系列重要的炎症研究 胃肠道和肝脏疾病。通过创造独特的环境来培育新颖的研究 想法和互动，圣地亚哥消化疾病研究中心提供了一个独特的机会 整合临床和实验室研究，推进对消化系统疾病的基本了解，并增强 患有这些疾病的患者的健康和护理。

项目成果

The compact genome of Giardia muris reveals important steps in the evolution of intestinal protozoan parasites.

• DOI: 10.1099/mgen.0.000402
• 发表时间: 2020-08
• 期刊: Microbial genomics
• 影响因子: 3.9
• 作者: Xu F;Jiménez-González A;Einarsson E;Ástvaldsson Á;Peirasmaki D;Eckmann L;Andersson JO;Svärd SG;Jerlström-Hultqvist J
• 通讯作者: Jerlström-Hultqvist J

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.

• DOI: 10.1111/apt.16712
• 发表时间: 2022-03
• 期刊: ALIMENTARY PHARMACOLOGY & THERAPEUTICS
• 影响因子: 7.6
• 作者: Sandborn, William J.;Lawendy, Nervin;Danese, Silvio;Su, Chinyu;Loftus, Edward V., Jr.;Hart, Ailsa;Dotan, Iris;Damiao, Aderson O. M. C.;Judd, Donna T.;Guo, Xiang;Modesto, Irene;Wang, Wenjin;Panes, Julian
• 通讯作者: Panes, Julian

Characterization of Metronidazole-Resistant Giardia intestinalis Lines by Comparative Transcriptomics and Proteomics.

• DOI: 10.3389/fmicb.2022.834008
• 发表时间: 2022
• 期刊: Frontiers in microbiology
• 影响因子: 5.2
• 作者: Krakovka S;Ribacke U;Miyamoto Y;Eckmann L;Svärd S
• 通讯作者: Svärd S

Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.

• DOI: 10.1111/apt.16626
• 发表时间: 2021-12
• 期刊: ALIMENTARY PHARMACOLOGY & THERAPEUTICS
• 影响因子: 7.6
• 作者: Feagan, Brian G.;Khanna, Reena;Sandborn, William J.;Vermeire, Severine;Reinisch, Walter;Su, Chinyu;Salese, Leonardo;Fan, Haiyun;Paulissen, Jerome;Woodworth, Deborah A.;Niezychowski, Wojciech;Sands, Bruce E.
• 通讯作者: Sands, Bruce E.

(Pro)renin Receptor Knockdown Attenuates Liver Fibrosis Through Inactivation of ERK/TGF-β1/SMAD3 Pathway.

• DOI: 10.1016/j.jcmgh.2021.05.017
• 发表时间: 2021
• 期刊: Cellular and molecular gastroenterology and hepatology
• 影响因子: 7.2
• 作者: Hsieh YC;Lee KC;Lei HJ;Lan KH;Huo TI;Lin YT;Chan CC;Schnabl B;Huang YH;Hou MC;Lin HC
• 通讯作者: Lin HC